New research shows an AI-powered chatbot trained to deliver cognitive behavioral therapy significantly reduced anxiety, ...

Amgen said the Food and Drug Administration approved Uplizna for Immunoglobulin G4-related disease, the second approved indication. The biotechnology company said Thursday the FDA granted breakthrough ...

After some high-profile crashes, the one-time biotech darling is inching toward success with its Hunter syndrome treatment, ...

Amgen (AMGN) announced that the U.S. FDA has approved Uplizna as the first and only treatment for adults living with Immunoglobulin G4-related ...

Ideaya Biosciences (IDYA) announced that the FDA has granted breakthrough therapy designation for darovasertib, a protein kinase C inhibitor, ...

The FDA’s decision to grant Breakthrough Therapy Designation to UPLIZNA underscores the significant unmet medical need in ...

NMPA Breakthrough Therapy Designation is intended to facilitate and expedite the development and review of investigational drugs for serious diseases or conditions when preliminary clinical ...

Yingli Pharma has obtained US FDA approval for a Phase III trial of linperlisib for R/R peripheral T-cell lymphoma (PTCL).

Vision is one of the most crucial human senses, yet over 300 million people worldwide are at risk of vision loss due to ...

Although itolizumab did not improve response rates at Day 29 for patients with acute GVHD, the therapy showed significant ...

Brian Fiske, chief scientist at The Michael J. Fox Foundation for Parkinson’s Research, which funded some of Dr ...

has granted Breakthrough Therapy Designation (BTD) for IBI363, a first-in-class PD-1/IL-2 α-bias bispecific antibody fusion protein, as monotherapy for the treatment of unresectable locally ...